Literature DB >> 16826552

Drug compliance, co-payment and health outcomes: evidence from a panel of Italian patients.

Vincenzo Atella1, Franco Peracchi, Domenico Depalo, Claudio Rossetti.   

Abstract

This paper studies the relationship between medical compliance and health outcomes - hospitalization and mortality rates - using a large panel of patients residing in a local health authority in Italy. These data allow us to follow individual patients through all their accesses to public health care services until they either die or leave the local health authority. We adopt a disease specific approach, concentrating on hypertensive patients treated with ACE-inhibitors. Our results show that medical compliance has a clear effect on both hospitalization and mortality rates: health outcomes clearly improve when patients become more compliant to drug therapy. At the same time, we are able to infer valuable information on the role that drug co-payment can have on compliance, and as a consequence on health outcomes, by exploiting the presence of two natural experiments during the period of analysis. Our results show that drug co-payment has a strong effect on compliance, and that this effect is immediate. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2006        PMID: 16826552     DOI: 10.1002/hec.1135

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  12 in total

Review 1.  How does copayment for health care services affect demand, health and redistribution? A systematic review of the empirical evidence from 1990 to 2011.

Authors:  Astrid Kiil; Kurt Houlberg
Journal:  Eur J Health Econ       Date:  2013-08-29

2.  Sources of Support for Studies That Inform Recommendations of the Community Preventive Services Task Force.

Authors:  Elizabeth Neilson; Jennifer Villani; Shawna L Mercer; David L Tilley; Isaah Vincent; Anita Alston; Carrie N Klabunde
Journal:  Public Health Rep       Date:  2020-10-13       Impact factor: 2.792

3.  The impact of cost-sharing schemes on drug compliance in Italy: evidence based on quantile regression.

Authors:  Vincenzo Atella; Joanna Aleksandra Kopinska
Journal:  Int J Public Health       Date:  2013-12-15       Impact factor: 3.380

4.  Investigating the cost implications of including all respiratory medicines in PCRS schemes.

Authors:  Jackie O'Dwyer; Aileen Murphy
Journal:  Ir J Med Sci       Date:  2018-02-01       Impact factor: 1.568

5.  Changes in equity in out-of-pocket payments during the period of health care reforms: evidence from Hungary.

Authors:  Petra Baji; Milena Pavlova; László Gulácsi; Wim Groot
Journal:  Int J Equity Health       Date:  2012-07-24

6.  Navigating through the maze of pricing and affordability of branded pharmaceuticals in the midst of the financial crisis: a comparative study among five European recession countries, from a Cyprus perspective.

Authors:  Panagiotis Petrou; Michael A Talias
Journal:  J Pharm Policy Pract       Date:  2016-03-15

Review 7.  The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis.

Authors:  Sarah-Jo Sinnott; Claire Buckley; David O'Riordan; Colin Bradley; Helen Whelton
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

8.  What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries.

Authors:  Marin C Gemmill; Sarah Thomson; Elias Mossialos
Journal:  Int J Equity Health       Date:  2008-05-02

9.  Factors affecting medication adherence in Lebanese patients with chronic diseases.

Authors:  Amal Al-Hajje; Sanaa Awada; Samar Rachidi; Salam Zein; Wafa Bawab; Zeinab El-Hajj; Mayssam Bou Zeid; Mohammad Yassine; Pascale Salameh
Journal:  Pharm Pract (Granada)       Date:  2015-06-15

Review 10.  Reducing Medication Costs to Prevent Cardiovascular Disease: A Community Guide Systematic Review.

Authors:  Gibril J Njie; Ramona K C Finnie; Sushama D Acharya; Verughese Jacob; Krista K Proia; David P Hopkins; Nicolaas P Pronk; Ron Z Goetzel; Thomas E Kottke; Kimberly J Rask; Daniel T Lackland; Lynne T Braun
Journal:  Prev Chronic Dis       Date:  2015-11-25       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.